Gritstone bio, Inc. (GRTS)

0,9627 +0,0927 (+10,66%) Alla chiusura: 04:00PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 231

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, President, CEO & Director	983,44k	N/D	1966
Mr. Erin E. Jones M.S.	Executive VP & COO	658,01k	N/D	1972
Dr. Karin Jooss Ph.D.	Executive VP and Head of Research & Development	706,07k	N/D	1965
Ms. Vassiliki Economides	Executive VP & CFO	N/D	N/D	1981
Mr. James Cho	Chief Accounting Officer	N/D	N/D	N/D
George MacDougall	Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Stacy Proctor	Executive VP & Chief People Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Governance aziendale

L'ISS Governance QualityScore di Gritstone bio, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 3; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.